PROVENTION BIO, INC.
PROVENTION BIO, INC. (PBI): 7 pipeline candidates · ~61 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
60.9 months
D/E 0.94 · 0% dilution
Lead: Approved
7 candidates
N/A
N/A
A transparent, data-derived signal for PROVENTION BIO, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$2.4B
Cash
$44.0M
Quarterly Burn
$8.0M
Runway
60.9 mo
Revenue
$10.8M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| ordesekimab | Phase 2 |
| prv-015 | Phase 2 |
| prv-031 | BLA Filed |
| prv-101 | Preclinical |
| prv-3279 | Phase 2 |
| teplizumab | BLA Filed |
| tzield | Approved |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
316
Total value held
$1.18B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 14,673,861 | $162.1M |
| vanguard capital management llc | 12,119,252 | $133.9M |
| vanguard portfolio management llc | 8,398,571 | $92.8M |
| state street corp | 6,417,472 | $70.9M |
| geode capital management, llc | 3,758,123 | $41.5M |
| goldman sachs group inc | 3,573,304 | $39.5M |
| capital management corp /va | 2,689,543 | $29.7M |
| dimensional fund advisors lp | 2,331,315 | $25.8M |
| morgan stanley | 2,275,231 | $25.1M |
| charles schwab investment management inc | 2,160,613 | $23.9M |
Showing top 10 of 316 institutional holders of PROVENTION BIO, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in PROVENTION BIO, INC.'s pipeline?
PROVENTION BIO, INC. (PBI) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is PROVENTION BIO, INC.'s lead drug candidate?
PROVENTION BIO, INC.'s most advanced tracked candidate is ordesekimab (Phase 2) for Gluten-free diet non-responsive celiac disease (NRCD).
What is PROVENTION BIO, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, PROVENTION BIO, INC. has approximately 60.9 months of cash runway.
What is PROVENTION BIO, INC.'s market capitalization?
PROVENTION BIO, INC.'s market capitalization is approximately $2.4B.
Who is the CEO of PROVENTION BIO, INC.?
Mr. Kurtis James Wolf is the chief executive officer of PROVENTION BIO, INC. (PBI).
Get the full picture on PROVENTION BIO, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.